# Wegovy Tablet vs Wegovy Injection: Which Will the NHS Fund?
Both forms of Wegovy contain the same active ingredient — semaglutide — and both have received MHRA marketing authorisation in the UK. The injection was approved in 2023. The tablet was approved on 11 June 2026. But NHS availability and private prescription status differ significantly between the two, and understanding that difference is essential before deciding which route to pursue.
Here is the honest picture, as of June 2026.
> Wegovy tablets and Wegovy injections are prescription-only medicines. Always consult a qualified healthcare professional before starting or changing treatment.
—
## Wegovy injection on the NHS: the reality
Wegovy (semaglutide 2.4mg weekly injection) received a NICE recommendation for NHS use in 2023, making it theoretically available through the NHS. The practical reality is considerably more restricted.
NHS access to injectable Wegovy is limited to patients who meet all of the following criteria:
– **BMI of 40 kg/m² or above** (or BMI 35–39.9 with a serious weight-related health condition, in some specialist pathways)
– Referred to and accepted by a **specialist weight management service** (also called a Tier 3 or Tier 4 service)
– Actively participating in a structured lifestyle intervention alongside the medication
– No contraindications to semaglutide
These criteria are significantly more restrictive than the private prescribing eligibility threshold (BMI 30+, or 27+ with a comorbidity). The vast majority of people who might benefit from injectable Wegovy do not qualify for NHS access under current criteria.
Even for those who do meet the criteria, capacity in NHS specialist weight management services is severely constrained. Many services have waiting times of 12–24 months or longer. Supply shortages of injectable semaglutide products have further complicated NHS rollout since 2023.
In practice, most people who want Wegovy injection and can afford it access it through private prescription services — at prices typically ranging from £150–£250 per month for the maintenance dose.
—
## Wegovy tablet on the NHS: not yet
As of June 2026, oral Wegovy is not available on the NHS under any circumstances. The MHRA approved the tablet on 11 June 2026 — but MHRA approval and NHS funding are separate processes.
For NHS funding, NICE must complete a Technology Appraisal and issue a positive recommendation. That process has not begun for oral Wegovy. Based on the typical NICE timeline (18–24 months from initiation), NHS oral Wegovy access is unlikely before late 2028 at the earliest, and would almost certainly come with similarly restrictive criteria to those applied to the injection.
There is a possibility that NICE could choose to evaluate both formulations together, or that the oral formulation’s more accessible dosing (no injection, no sharps disposal, no weekly schedule) could influence access criteria — but this is speculative, and no NICE scoping document has been published as of the date of this article.
—
## The private prescription market: tablet vs injection
For patients accessing treatment privately, both forms are legally available from GPhC-registered providers against a valid prescription.
**Injectable Wegovy (private):**
– Well-established market with numerous providers
– Prices typically £150–£250/month at maintenance dose (2.4mg weekly)
– Requires weekly self-injection (subcutaneous, usually abdomen, thigh, or upper arm)
– Auto-injector pen — no needle preparation required
**Oral Wegovy tablet (private):**
– Newly launched — seven providers taking pre-orders as of June 2026
– Prices from £64/month at starting dose (1.5mg)
– Prices will rise with dose escalation; maintenance dose (25mg) pricing not yet fully established
– Once-daily oral tablet — no injections
– Requires 30-minute fasting window after taking (water only, max 120ml)
The oral tablet’s starting-dose price advantage over the injection is meaningful. However, once dose escalation to 25mg is complete, the price gap between the two formulations is less certain — providers have not yet published full pricing for higher oral Wegovy doses, and the maintenance-dose market will take several months to establish.
—
## Which formulation should you choose?
This is a clinical question, and the answer depends on individual circumstances that only a healthcare professional can properly assess. That said, some general considerations apply:
**Oral Wegovy tablet may be preferable if:**
– You prefer not to inject yourself
– You are starting treatment for the first time and want the lowest cost entry point
– The weekly injection schedule is inconvenient for your lifestyle
**Injectable Wegovy may be preferable if:**
– You have been using the injection successfully and your prescriber advises continuing
– The 30-minute morning fasting window is genuinely impractical for your routine
– You need a faster route to higher therapeutic doses (the injection reaches maintenance dose in about 16 weeks; the oral escalation takes approximately 6 months)
There is no clinical evidence that one formulation is more effective than the other for a given individual. The OASIS trials (oral) and STEP trials (injection) showed comparable average weight loss over similar timeframes — but were separate studies in different populations, so a direct comparison is not straightforward.
—
## Compare oral Wegovy prices now
If you are considering the oral tablet route, our comparison table shows all seven pre-order providers with verified prices, true first-month costs, and delivery information.
[Compare all Wegovy tablet providers →](/providers/)
To track both oral and injectable options, [sign up for our price alert service](/providers/).
—
*This article is for informational purposes only and does not constitute medical advice. Wegovy is a prescription-only medicine in both tablet and injectable forms. Always consult a qualified healthcare professional before starting, stopping, or changing any weight management treatment. CompareWegovyPrices.co.uk is not affiliated with Novo Nordisk.*
